SCHEMBL830005

SCHEMBL830005

Cn1c(=O)cc(Sc2ccc(F)cc2)c2cccnc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AHR P35869 1/20 0.42
HPGD P15428 1/20 0.42
FEN1 P39748 1/20 0.42
KMT2A Q03164 1/20 0.40
TNKS O95271 1/20 0.39
GRM4 Q14833 1/20 0.38
MAPT P10636 1/20 0.38
TP53 P04637 1/20 0.38
LMNA P02545 1/20 0.37
HTT P42858 1/20 0.37
POLB P06746 1/20 0.37
EGFR P00533 1/20 0.37
SRC P12931 1/20 0.37
EP300 Q09472 1/20 0.36
CREBBP Q92793 1/20 0.36
KAT2A Q92830 1/20 0.36
KAT2B Q92831 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPK14 Q16539 1/20 0.36
LCK P06239 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL830438 0.88 HPGD (0.43) HPGDFEN1KMT2ATNKSMAPT
SCHEMBL829817 0.87 FEN1 (0.42) HPGDFEN1KMT2ATNKSGRM4
SCHEMBL829969 0.87 FEN1 (0.42) FEN1KMT2ATNKSMAPTTP53
SCHEMBL830491 0.87 TNKS (0.47) HPGDFEN1KMT2ATNKSMAPT
SCHEMBL13923062 0.80 FEN1 (0.48) HPGDFEN1KMT2ATNKSGRM4
SCHEMBL836028 0.78 KDM4E (0.51) HPGDKMT2AMAPTTP53LMNA
SCHEMBL835002 0.75 RXFP1 (0.45) KMT2AMAPTLMNAHTTPOLB
SCHEMBL835229 0.73 NQO2 (0.42) MAPTTP53LMNAHTTPOLB
SCHEMBL25703950 0.72 NQO2 (0.54) HPGDFEN1KMT2ATNKSGRM4
SCHEMBL835284 0.72 RXFP1 (0.43) HPGDKMT2AMAPTTP53LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143276-B2 4-thio substituted quinoline and naphthyridine compounds XTL BIOPHARMACEUTICALS LTD. (IL) 2012-03-27 US disclosed
US-8143276-B2 4-thio substituted quinoline and naphthyridine compounds XTL BIOPHARMACEUTICALS LTD. (IL) 2012-03-27 US disclosed
US-8143276-B2 4-thio substituted quinoline and naphthyridine compounds XTL BIOPHARMACEUTICALS LTD. (IL) 2012-03-27 US disclosed
EP-2061466-A2 4-THIO SUBSTITUTED QUINOLINE AND NAPHTHYRIDINE COMPOUNDS Xtl Biopharmaceuticals Ltd. (US) 2009-05-27 EP disclosed
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds PRESIDIO PHARMACEUTICALS, INC. 2009-02-26 US disclosed
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds PRESIDIO PHARMACEUTICALS, INC. 2009-02-26 US disclosed
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds PRESIDIO PHARMACEUTICALS, INC. 2009-02-26 US disclosed
WO-2008024423-A2 4-THIO SUBSTITUTED QUINOLINE AND NAPHTHYRIDINE COMPOUNDS XTL BIOPHARMACEUTICALS LTD. (US) 2008-02-28 WO disclosed
WO-2008024423-A2 4-THIO SUBSTITUTED QUINOLINE AND NAPHTHYRIDINE COMPOUNDS XTL BIOPHARMACEUTICALS LTD. (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds GTF3C4, HNF4A, TENT4A AHR 1467/4885HPGD 2113/4885FEN1 2320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.